Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Activated protein C inhibits neutrophil migration in allergic asthma: a randomised trial.

de Boer JD, Berger M, Majoor CJ, Kager LM, Meijers JC, Terpstra S, Nieuwland R, Boing AN, Lutter R, Wouters D, van Mierlo GJ, Zeerleder SS, Bel EH, van't Veer C, de Vos AF, van der Zee JS, van der Poll T.

Eur Respir J. 2015 Dec;46(6):1636-44. doi: 10.1183/13993003.00459-2015. Epub 2015 Sep 17.

2.

Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab.

van Bijnen ST, Wouters D, van Mierlo GJ, Muus P, Zeerleder S.

J Thromb Haemost. 2015 Nov;13(11):2004-11. doi: 10.1111/jth.13125. Epub 2015 Oct 19.

3.

Increased intra- and extracellular granzyme expression in patients with tuberculosis.

Garcia-Laorden MI, Blok DC, Kager LM, Hoogendijk AJ, van Mierlo GJ, Lede IO, Rahman W, Afroz R, Ghose A, Visser CE, Md Zahed AS, Husain MA, Alam KM, Chandra Barua P, Hassan M, Hossain A, Tayab MA, Day N, Dondorp AM, de Vos AF, van der Poll T.

Tuberculosis (Edinb). 2015 Sep;95(5):575-80. doi: 10.1016/j.tube.2015.05.016. Epub 2015 Jun 20.

PMID:
26156785
4.

Nucleosomes and neutrophil activation in sickle cell disease painful crisis.

Schimmel M, Nur E, Biemond BJ, van Mierlo GJ, Solati S, Brandjes DP, Otten HM, Schnog JJ, Zeerleder S; Curama Study Group.

Haematologica. 2013 Nov;98(11):1797-803. doi: 10.3324/haematol.2013.088021. Epub 2013 Aug 2.

5.

The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab.

van Mierlo GJ, Cnubben NH, Wouters D, Wolbink GJ, Hart MH, Rispens T, Ganderup NC, Kuper CF, Aarden L, Penninks AH.

J Immunotoxicol. 2014 Jan-Mar;11(1):62-71. doi: 10.3109/1547691X.2013.796023. Epub 2013 Jun 5.

PMID:
23738746
6.

The Göttingen minipig® as an alternative non-rodent species for immunogenicity testing: a demonstrator study using the IL-1 receptor antagonist anakinra.

van Mierlo GJ, Cnubben NH, Kuper CF, Wolthoorn J, van Meeteren-Kreikamp AP, Nagtegaal MM, Doornbos R, Ganderup NC, Penninks AH.

J Immunotoxicol. 2013 Jan-Mar;10(1):96-105. doi: 10.3109/1547691X.2012.735274. Epub 2012 Nov 7.

PMID:
23134195
7.

Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis.

van Montfoort ML, Stephan F, Lauw MN, Hutten BA, Van Mierlo GJ, Solati S, Middeldorp S, Meijers JC, Zeerleder S.

Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):147-51. doi: 10.1161/ATVBAHA.112.300498. Epub 2012 Oct 25.

PMID:
23104849
8.

Cutting edge: TNFR-shedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators.

van Mierlo GJ, Scherer HU, Hameetman M, Morgan ME, Flierman R, Huizinga TW, Toes RE.

J Immunol. 2008 Mar 1;180(5):2747-51.

9.

Apolipoprotein C-I is crucially involved in lipopolysaccharide-induced atherosclerosis development in apolipoprotein E-knockout mice.

Westerterp M, Berbée JF, Pires NM, van Mierlo GJ, Kleemann R, Romijn JA, Havekes LM, Rensen PC.

Circulation. 2007 Nov 6;116(19):2173-81. Epub 2007 Oct 22.

PMID:
17967778
10.

Dendritic cells: vehicles for tolerance induction and prevention of autoimmune diseases.

van Duivenvoorde LM, van Mierlo GJ, Boonman ZF, Toes RE.

Immunobiology. 2006;211(6-8):627-32. Epub 2006 Jul 5. Review.

PMID:
16920501
11.

Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model.

Heijnen BH, Straatsburg IH, Padilla ND, Van Mierlo GJ, Hack CE, Van Gulik TM.

Clin Exp Immunol. 2006 Jan;143(1):15-23.

12.

Maintenance of immune tolerance depends on normal tissue homeostasis.

Boonman ZF, van Mierlo GJ, Fransen MF, de Keizer RJ, Jager MJ, Melief CJ, Toes RE.

J Immunol. 2005 Oct 1;175(7):4247-54.

13.

CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.

den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE.

Cancer Res. 2005 Aug 1;65(15):6984-9.

14.
15.

Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.

Familian A, Voskuyl AE, van Mierlo GJ, Heijst HA, Twisk JW, Dijkmans BA, Hack CE.

Ann Rheum Dis. 2005 Jul;64(7):1003-8.

16.

Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.

van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ.

J Immunol. 2004 Dec 1;173(11):6753-9.

17.
18.

Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction.

Boonman ZF, van Mierlo GJ, Fransen MF, Franken KL, Offringa R, Melief CJ, Jager MJ, Toes RE.

J Immunol. 2004 Feb 1;172(3):1567-74.

19.

Rat C-reactive protein activates the autologous complement system.

Diaz Padilla N, Bleeker WK, Lubbers Y, Rigter GM, Van Mierlo GJ, Daha MR, Hack CE.

Immunology. 2003 Aug;109(4):564-71.

20.

Elevated nucleosome levels in systemic inflammation and sepsis.

Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld AB, Caliezi C, van Nieuwenhuijze AE, van Mierlo GJ, Eerenberg AJ, Lämmle B, Hack CE.

Crit Care Med. 2003 Jul;31(7):1947-51.

PMID:
12847387
21.

Circulating concentrations of soluble granzyme A and B increase during natural and experimental Plasmodium falciparum infections.

Hermsen CC, Konijnenberg Y, Mulder L, Loé C, van Deuren M, van der Meer JW, van Mierlo GJ, Eling WM, Hack CE, Sauerwein RW.

Clin Exp Immunol. 2003 Jun;132(3):467-72.

22.

Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection.

Groeneveld AB, Tacx AN, Bossink AW, van Mierlo GJ, Hack CE.

Clin Immunol. 2003 Feb;106(2):106-15.

PMID:
12672401
23.

In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 costimulatory pathway.

Diehl L, van Mierlo GJ, den Boer AT, van der Voort E, Fransen M, van Bostelen L, Krimpenfort P, Melief CJ, Mittler R, Toes RE, Offringa R.

J Immunol. 2002 Apr 15;168(8):3755-62.

24.

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.

van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE.

Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5561-6. Epub 2002 Apr 2.

25.

Circulating inflammatory mediators in patients with fever: predicting bloodstream infection.

Groeneveld AB, Bossink AW, van Mierlo GJ, Hack CE.

Clin Diagn Lab Immunol. 2001 Nov;8(6):1189-95.

26.

The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model.

Bos IG, van Mierlo GJ, Bleeker WK, Rigter GM, te Velthuis H, Dickneite G, Hack CE.

Int Immunopharmacol. 2001 Aug;1(8):1583-95.

PMID:
11515821
27.

Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance.

den Boer AT, Diehl L, van Mierlo GJ, van der Voort EI, Fransen MF, Krimpenfort P, Melief CJ, Offringa R, Toes RE.

J Immunol. 2001 Sep 1;167(5):2522-8.

28.

Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein.

Molenaar ET, Voskuyl AE, Familian A, van Mierlo GJ, Dijkmans BA, Hack CE.

Arthritis Rheum. 2001 May;44(5):997-1002.

29.

IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer.

Ogilvie AC, Hack CE, Wagstaff J, van Mierlo GJ, Erenberg AJ, Thomsen LL, Hoekman K, Rankin EM.

J Immunol. 1996 Jan 1;156(1):389-94.

PMID:
8598489

Supplemental Content

Loading ...
Support Center